Suppressors of the *cdc-25.1(gf)*-associated intestinal hyperplasia reveal important maternal roles for *prp-8* and a subset of splicing factors in *C. elegans*

MICHAËL HEBEISEN, JOHN DRYSDALE, and RICHARD ROY

Department of Biology, McGill University, Montreal, Quebec, H3A 1B1, Canada

ABSTRACT

The maternal contribution of gene products enables embryos to initiate their developmental program in the absence of zygotic gene expression. In *Caenorhabditis elegans*, maternal CDC-25.1 levels are tightly regulated to promote early cell divisions, while stabilization of this phosphatase by gain-of-function mutations gives rise to intestinal-specific hyperplasia. To identify regulators of CDC-25.1 levels and/or function, we performed a modifier screen of the *cdc-25.1(gf)*-dependent hyperplasia. One of the isolated suppressor mutants possesses a donor splice site mutation in *prp-8*, a key splicing factor of the U5-specific snRNP. *prp-8(rr40)* produces aberrant *prp-8* splice variants that generate C-terminal truncations at the expense of wild-type *prp-8*. Levels of maternal transcripts are reduced, including *cdc-25.1*, while zygotic transcripts appear unperturbed, suggesting a germ-line-specific role for this splicing factor in regulating the splicing, and consequently, the steady-state levels of maternal transcripts. Using a novel feeding RNAi strategy we found that only a subset of splicing factors suppress *cdc-25.1(gf)*, suggesting that they too may play specific roles in germ-line spliceosome function. In humans, mutations in the corresponding hPrp8 C-terminal domain result in retinitis pigmentosa, a retinal-specific disorder. Intriguingly, despite affecting the general splicing apparatus, both human and *C. elegans* show tissue-specific defects resulting from mutations in this key splicing component. Our findings suggest that in addition to its important regulatory function in the *C. elegans* germ line, *prp-8(rr40)* may provide further insight into the etiology of this splicing-associated human disorder.

Keywords: maternal contribution; *cdc-25.1*; cell cycle; tissue specificity; *prp-8*; splicing factors; retinitis pigmentosa

INTRODUCTION

Many early embryonic events proceed under maternal control, driven by a largely unlimiting pool of mRNA and protein present in the oocyte and provided by the maternal germ line. This pool of gene products thus circumvents any requirement for the time- and energy-dependent assembly of transcription complexes and allows messages to be translated where and when necessary, while proteins can be efficiently deployed to critical regions of the developing embryo. Such maternal gene products contribute to diverse developmental processes that include axis specification, cell fate determination, and even cell cycle regulation.

From large-scale in situ hybridizations performed in the syncytial embryos of *Drosophila melanogaster*, it was shown that more than 65% of all genes are expressed in the maternal germ line and delivered to the developing oocyte in the form of mature transcripts, most of which are short lived and display precise localization patterns (Lecuyer et al. 2007). Microarray and EST analysis in mouse indicate that 25%–40% of all genes are deposited maternally in mature oocytes (Wang et al. 2004; Evsikov et al. 2006), while in *Xenopus* and most amphibians, the early embryonic developmental events rely entirely upon maternal contribution, until zygotic genes become activated at the mid-blastula transition (MBT) (Newport and Kirschner 1982; Heasman 2006). In *C. elegans*, the transition from maternal to zygotic developmental control occurs during embryogenesis and is subject to lineage- and gene-specific regulation (Bowerman 1998; DeRenzo and Seydoux 2004).

The early cell division cycle is controlled maternally in numerous embryos and often consists of rapid, successive S and M phases without intervening gap (G) phases (Edgar

Reprint requests to: Richard Roy, Department of Biology, McGill University, Stewart Biology Building, 1205 Dr. Penfield Avenue, Montreal, Quebec, H3A 1B1, Canada; e-mail: richard.roy@mcgill.ca; fax: (514) 398-5069.

Article published online ahead of print. Article and publication date are at <http://www.rnajournal.org/cgi/doi/10.1261/rna.1168408>.

and McGhee 1988; Edgar 1994; Kipreos 2005). The lengthening of these early cell division cycles is usually triggered by the degradation of key maternal cell cycle factors, marking the transition from the maternal to the zygotic control of the cell cycle machinery (O'Farrell et al. 1989; Edgar 1994). In *Drosophila*, the switch from the early embryonic rapid and synchronous cell division cycles to the introduction of gap phases relies on the depletion of both the *twine* and *string* maternal gene products, two Cdc25 orthologs (Edgar and Datar 1996; Edgar and Lehner 1996; Mata et al. 2000). Likewise, in *Xenopus*, Cdc25A becomes down-regulated after the developmentally controlled activation of an intra-S phase checkpoint to ensure the lengthening of the cell cycle at the MBT (Kim et al. 1999; Shimuta et al. 2002).

Cdc25 family phosphatases have been shown to play pivotal roles in the decision to proceed into S or M phases of the cell cycle by removing the Wee1-mediated inhibitory phosphorylation on cyclin-dependent kinases (CDKs) (Russell and Nurse 1987; Galaktionov and Beach 1991; Mueller et al. 1995). In higher eukaryotes like *Drosophila*, *Xenopus*, or mammals, the Cdc25 family consists of related, yet functionally distinct members. *C. elegans* has four members of the Cdc25 phosphatase family (Ashcroft et al. 1998), with maternal CDC-25.1 being essential for germ-line proliferation, completion of meiosis, and early embryonic divisions (Ashcroft and Golden 2002). These paralogs play redundant, but also unique and characteristic, phase-and/or tissue-specific roles (O'Farrell et al. 1989; Alphey et al. 1992; Courtot et al. 1992; Busino et al. 2004; Perdiguero and Nebreda 2004; Myer et al. 2005). Destabilization of Cdc25 phosphatases is under strict cell cycle and developmental regulation. In mammals, an SCF ubiquitin E3 ligase utilizes the β -TrCP F-box protein to recognize and target Cdc25A for proteasome-mediated degradation during an unperturbed S phase, while DNA damage accelerates this process in an ATM/ATR-Chk1/Chk2-dependent manner to halt the cell cycle (Falck et al. 2001; Busino et al. 2003; Jin et al. 2003; Sorensen et al. 2003). In *C. elegans*, two maternal-effect, *cdc-25.1* gain-of-function (*gf*) mutations alter residues within a destruction motif recognized by the *C. elegans* β -TrCP ortholog LIN-23, impairing the efficient SCF^{LIN-23}-mediated degradation of the CDC-25.1 phosphatase during a precise developmental window during embryogenesis, triggering supernumerary cell divisions exclusively in the intestine (Bao et al. 2008; Hebeisen and Roy 2008).

To uncover additional regulatory pathways that control CDC-25.1 levels, we performed a genetic modifier screen using the *cdc-25.1(rr31)gf* mutant (Kostic and Roy 2002). We report here the isolation of five genes that suppress the intestinal hyperplasia associated with *cdc-25.1(gf)*. We show that one suppressor, *rr40*, corresponds to a mutation, which results in a partial truncation of the C terminus of the *C. elegans* 220-kDa U5-specific snRNP ortholog PRP-8, an essential and key component of the spliceosome. We provide

evidence that *prp-8* plays important and essential roles in establishing and maintaining elevated levels of germ-line-specific gene products (maternal contribution) to sustain subsequent developmental processes throughout embryogenesis, including the proper regulation of cell division cycles. Moreover, when tested by RNAi, we show that only a subset of splicing factors act similar to *prp-8* and also suppress the *cdc-25.1(rr31)*-associated hyperplasia, suggesting that together these factors may play a unique role during germ-line and early embryonic development. Interestingly, mutations localized in the C terminus of the ubiquitous human protein hPrp8 have been associated with autosomal dominant retinitis pigmentosa (adRP), a retinal-specific hereditary disorder (McKie et al. 2001). The intriguing parallels that exist between the human adRP and *C. elegans* *prp-8(rr40)* indicate that this mutant may be used to study the genetic and molecular events associated with adRP.

RESULTS

Isolation of mutants that reduce the tissue-specific *cdc-25.1(rr31)*-associated intestinal hyperplasia

The intestinal hyperplasia associated with stabilized CDC-25.1(*gf*) protein indicates that the timely degradation of this cell cycle regulator is crucial for the proper formation of the digestive organ. To reveal additional pathways that contribute to CDC-25.1 phosphatase levels during embryogenesis and to uncover what gene products potentiate the *cdc-25.1(gf)*-associated overproliferation, we performed an EMS-based suppressor screen in the *cdc-25.1(rr31)* gain-of-function background and selected for viable animals with a reduction of the intestinal hyperplasia (see Materials and Methods).

Five recessive, strict maternal effect mutations were isolated, each of which suppresses the *cdc-25.1(rr31)* phenotype from 50% to 100% (Fig. 1). In all cases, some animals displayed wild-type intestinal cell counts (20 cells), which is never observed in *cdc-25.1(rr31)* single mutants (data not shown). On the other hand, none of these suppressor mutants had less intestinal cells than the wild type, suggesting that their observed effect is not due to a general reduction in cell division, but rather to specific effects on *cdc-25.1(rr31)*. *cdc-25.1(rr31rr36)* corresponds to an intragenic mutation that restores the timely degradation of CDC-25.1(*rr31rr36*) by affecting a potential stabilizing motif/domain of the phosphatase, thereby suppressing the *cdc-25.1(rr31)*-associated hyperplasia (Hebeisen and Roy 2008). Complementation analysis suggests that the four other suppressors represent individual extragenic loci (data not shown).

rr40 displays pleiotropic and temperature-sensitive effects

Apart from its ability to suppress the embryonic intestinal hyperplasia of *cdc-25.1(rr31)* mutants, *rr40* displayed 26%

FIGURE 1. Isolation of five viable suppressors of the *cdc-25.1(rr31)*-associated intestinal hyperplasia. The average number of intestinal cells in L1 hatchlings (sample size $n > 50$) is indicated for each genotype at 20°C. All animals express the intestinal-specific *elt-2::gfp* marker that enables visualization and quantification of intestinal cells (Fukushige et al. 1999). Each of the suppressors (*rr36*–*rr40*) reduces the *cdc-25.1(rr31)*-associated intestinal hyperplasia specifically during embryogenesis, with no post-embryonic effect. *rr36* is the strongest suppressor and corresponds to an intragenic mutation in the *cdc-25.1* gene (Hebeisen and Roy 2008). *cdc-25.1(ij48)* corresponds to a second gain-of-function allele of the phosphatase that produces intestinal-specific hyperplasia similar to *cdc-25.1(rr31)* (Clucas et al. 2002). *ij48* and *rr31* both affect residues of the highly conserved DSG(X)₄S destruction motif. Error bars represent standard deviation.

embryonic (Emb) and early larval lethality (Lvl) ($n = 2837$) at 20°C together with a high incidence of male (Him) phenotype of 5.3% ($n = 747$), suggesting that *rr40* may affect some aspects of meiotic progression or chromosome segregation. A fraction of hermaphrodites also showed sterility (Ste), while some had protruding, fragile, or multivulvae (Pvl, Rup, Muv), indicating that *rr40* displays pleiotropic effects that affect animal development at different stages. The severity of these phenotypes varied with temperature. Temperature-shift experiments revealed that larvae downshifted before the L3 stage were fertile and had average brood sizes of ~200 eggs with 20% embryonic lethality, while those downshifted after the L3 stage exhibited increasing and irreversible sterility. The few animals that produced eggs in the later downshifts had brood sizes of <10 eggs, among which ~50% died during embryogenesis or at an early larval stage (Fig. 2, downshifts; data not shown). Complete sterility was detected in animals upshifted before the L3 stage, while penetrant embryonic/larval lethality (>95%) was observed in the progeny of fertile L4 or adult animals upshifted to the restrictive temperature (Fig. 2, upshifts; data not shown). Control *cdc-25.1(rr31)* mutants remain fertile and develop normally at 25°C (data not shown).

Thus, it appears that the *rr40* gene product is required during and after the L3 stage to promote gametogenesis and throughout the subsequent stages to maintain the production of germ cells. These results, together with its maternal effect, suggest that *rr40* functions mainly in the developing hermaphrodite germ line.

rr40 specifically suppresses the extra intestinal divisions observed in *cdc-25.1(gf)* mutants

To address whether *rr40* affects intestinal cell divisions during embryonic or post-embryonic development, we quantified the number of intestinal cells in *cdc-25.1(rr31); rr40* hatchlings. These early L1 larvae had a reduced

FIGURE 2. The *rr40* gene product is required from L3 to adulthood to produce and maintain a functional germ line. Reciprocal temperature-shift assays for *cdc-25.1(rr31); rr40* suppressors demonstrate two major requirements for the *rr40* gene product. Upshifts from 15°C (permissive) to 25°C (restrictive) are represented by black lines; downshifts from 25°C to 15°C by gray lines. (A) A first temperature-sensitive period is detected between the larval L3 and L4 stages, where *rr40* is required to establish a functional gamete-producing germ line. (B) *rr40* is also required continuously from the L3 stage until adulthood to maintain a normal brood size and to avoid the rapid and penetrant embryonic and early larval lethality detected in fertile adults that have been shifted at the restrictive temperature.

number of intestinal cells compared with *cdc-25.1(rr31)* single mutants (Fig. 1), while 32% possessed wild-type numbers of cells ($n = 100$) (Fig. 3B, bottom). To determine whether *rr40* specifically suppresses the supernumerary divisions caused by *cdc-25.1(rr31)* after the E⁸ stage, or whether it eliminates another round of division during embryogenesis to indirectly compensate, we performed lineage analysis on *cdc-25.1(rr31); rr40* embryos (Fig. 3A). We found that the supernumerary cell divisions caused by *cdc-25.1(rr31)* were specifically eliminated in ~35% of the *cdc-25.1(rr31); rr40* embryos ($n = 16$), allowing these cells to undergo the correct division pattern to produce the wild-type complement of intestinal cells (Fig. 3B, top left panel). No defect was observed in either the nuclear divisions or in the endocycles that occur after the L1 stage in the *C. elegans* intestine (data not shown).

FIGURE 3. *rr40* specifically suppresses the *cdc-25.1(rr31)*-associated supernumerary intestinal cell divisions. (A) A representative lineage map of the embryonic intestinal (E) lineage of *cdc-25.1(rr31)* mutants is shown alongside those of wild-type (left) and *cdc-25.1(rr31); rr40* suppressors (right). E represents the founder endodermal cell specified at the embryonic 7-cell stage and the number of E descendants in wild type is indicated on the left. All animals express integrated *end-3::gfp* and *elt-2::gfp* transgenes, which together mark the intestinal nuclei from the embryonic E² stage onward. The gray box highlights the supernumerary round of division that occurs during the E⁸ stage in *cdc-25.1(rr31)* and causes intestinal hyperplasia. Time scale is indicated on the right in minutes after fertilization. (B) Representative *elt-2::gfp* expressing 300-min-old embryos (top) and L1 hatchlings (bottom) demonstrating the *rr40*-mediated suppression (right) of the *cdc-25.1(rr31)*-associated extra cell divisions (middle). Thirty-two percent of the *cdc-25.1(rr31); rr40* suppressors were phenotypically indistinguishable from wild-type animals at 20°C (left). Scale bars, 10 μm.

To further confirm that *rr40* does not simply impair cell divisions generally throughout embryogenesis, we tested whether *rr40* would affect cell numbers independent of *cdc-25.1(rr31)* by generating *rr40* single mutants. These animals consistently possessed wild-type numbers of intestinal cells and nuclei and showed the same pleiotropic spectrum of phenotypes as well as the temperature sensitivity previously described for *cdc-25.1(rr31); rr40* double-mutant animals. Finally, to determine whether the *rr40*-mediated suppression was specific to the *cdc-25.1(rr31)* allele, *rr40* was examined for its ability to suppress the intestinal hyperplasia of a second *cdc-25.1(ij48)* gain-of-function mutation that affected the same destruction motif (Clucas et al. 2002). *rr40* similarly suppressed this *cdc-25.1(ij48)* allele (Fig. 1), suggesting that it is able to interfere with the cell cycle defect associated with these stabilized CDC-25.1(gf) proteins.

Taken together, these observations indicate that *rr40* is a specific, maternal effect suppressor of the *cdc-25.1(gf)*-associated intestinal hyperplasia, while causing temperature-sensitive pleiotropies throughout development.

rr40 affects *prp-8*, a crucial and highly conserved component of the spliceosome

We mapped and cloned *rr40* using SNP-Snip, deficiency, and 3-point mapping approaches, together with a novel hypomorphic feeding RNAi strategy (Materials and Methods; Supplemental Fig. S1). A single RNAi clone that corresponds to *prp-8* (C50C3.6) fully suppressed the *cdc-25.1(rr31)*-associated hyperplasia and phenocopied the pleiotropic effects of *rr40* (Fig. 4A; data not shown). *prp-8* is an essential gene and *prp-8(RNAi)* causes 100% sterility or embryonic lethality (Gonczy et al. 2000; Kamath et al. 2003). Thus, *prp-8(rr40)* likely corresponds to a hypomorphic allele. To identify the nature of the *rr40* molecular lesion, we sequenced the *prp-8* gene in *cdc-25.1(rr31); prp-8(rr40)* suppressors. An EMS typical base-pair substitution (G7337A) was detected at the second-last donor splice site of the *prp-8* genomic sequence, which was confirmed by demonstrating the formation of a *StyI* restriction fragment polymorphism in the mutant genomic sequence (Fig. 4B). Thus, the invariant GU nucleotides that mark the 5' intron boundary are converted to AU in the affected *prp-8(rr40)* intron (Fig. 4A).

PRP-8 corresponds to the *C. elegans* U5-specific small nuclear ribonucleoprotein (snRNP) orthologous to the *Saccharomyces cerevisiae* Prp8p, the *Drosophila* prp8 (CG8877), and the human U5-specific 220-kDa protein hPrp8. This spliceosomal component is one of the largest and most highly conserved nuclear proteins among eukaryotes, displaying 58% identity between *C. elegans* and *S. cerevisiae* and 86% identity between *C. elegans* and human (Hodges et al. 1995). Prp8 was first identified in yeast in a screen for temperature-sensitive lethal mutations

FIGURE 4. Genetic mapping of *rr40* indicates that it corresponds to an allele of the highly conserved U5-specific snRNP component *prp-8*. (A) Meiotic mapping in *cdc-25.1(rr31)* was used to place *rr40* to the left of linkage group III between the visible markers *unc-36* and *sma-3*. Feeding RNAi against the 26 genes present in this interval revealed that only *C50C3.6(RNAi)* phenocopied the *rr40* suppression. Independent sequence analysis indicated that *rr40* disrupts the second-last intron donor splice site of the *prp-8* gene, converting the highly conserved GT donor sequence to AT and creating a *StyI* restriction polymorphism (underlined sequence). (B) *StyI*-digested PCR amplification products of wild-type and *prp-8(rr40)* genomic DNA confirm the G7337A mutation generated by *rr40*.

(Hartwell, 1967) and characterized for its role in pre-mRNA processing (Vijayraghavan et al. 1989), where it plays central roles in the 5' and 3' splice site recognition of pre-mRNAs in addition to its function in the extensive remodeling steps that occur during spliceosomal activation and in both catalytic transesterification reactions (Teigelkamp et al. 1995; Grainger and Beggs 2005).

prp-8(rr40) affects the correct splicing of its own intron

The accuracy of the splice site sequences is crucial for the precise recognition and removal of introns by the spliceosome. Therefore, we wondered whether the affected donor splice site in *prp-8(rr40)* pre-mRNA would perturb the proper splicing events of that particular intron, a process in which PRP-8 itself plays a critical role.

To reveal the splicing events that occur at the splice site affected by *rr40* between exon 8 and intron 8 of *prp-8(rr40)*, the sequences of the mRNA species that span from the middle of exon 8 to the middle of exon 10 in wild-type and *prp-8(rr40)* animals were amplified by semiquantitative RT-PCR (see Materials and Methods) (Fig. 5A). Instead of the single wild-type amplification product detected in control animals, two bands appeared in the *cdc-25.1(rr31); prp-8(rr40)* suppressor, the levels of which were reduced

compared with the control (Fig. 5B). Sequence analysis of these two products indicated that intron 9 was spliced correctly in all cases, providing an internal control for spliceosomal efficiency and excluding the possibility of DNA contamination. This analysis revealed the presence of at least three different *rr40* splice variants (Fig. 5B). The first sequence corresponded to the expected wild-type *prp-8* message (356 nucleotides [nt]), indicating that it had been properly spliced despite its unconventional AU 5' donor splice site. The second sequence corresponded to an aberrant message (366 nt) with a 10-nt intron inclusion produced by splicing of an unconventional UU 5' donor splice site at intron position +10 (Fig. 5B). The third sequence (478 nt) corresponded to a second aberrant message that retained the entire 122-nt intron. The translation of both aberrant messages is predicted to produce a truncated protein that would lack the C-terminal-most 138 amino acids, removing a regulatory region shown to be very conserved among orthologs and crucial for protein interactions with other splicing factors (Fig. 5C) (Grainger and Beggs 2005; Pena et al. 2007; Zhang et al. 2007).

In summary, we show that the donor splice site mutation present in the second last *prp-8(rr40)* intron affects its own splicing, producing multiple *prp-8* messages, two of which harbor premature termination codons (PTCs) in the C terminus due to intron inclusions and consequent frame-shifts, while also producing wild-type *prp-8* transcript, the levels of which are reduced.

Aberrant *prp-8(rr40)* transcripts are partially targeted by the NMD pathway

Our semiquantitative PCR data suggest that the wild-type *prp-8* mRNA levels may be reduced, to the advantage of the mutant variants, while these aberrant mRNAs may be targeted for degradation by the nonsense-mediated mRNA decay (NMD) surveillance pathway that recognizes transcripts with PTCs (Longman et al. 2007).

To confirm the effect of *prp-8(rr40)* on the levels of its own transcripts, we compared the *prp-8* mRNA levels in wild-type, *cdc-25.1(rr31)*, and *cdc-25.1(rr31); prp-8(rr40)* animals by quantitative Northern analysis using a probe complementary to an exon sequence present in all *prp-8(rr40)* variants. As expected, *prp-8* transcripts from control animals were detected as a single 7.4-kb band, whereas

FIGURE 5. Differentially spliced *prp-8* mRNA species are detected in *prp-8(rr40)* mutants. Total mRNA was isolated from wild-type, *cdc-25.1(rr31)*, *cdc-25.1(rr31); prp-8(rr40)*, and *smg-1(r861); prp-8(rr40)* mutants and reverse transcribed (RT) with polydT primers in a controlled, semiquantitative manner (Materials and Methods). (A) Primers used for PCR amplification were located in exon 8 (sense) and exon 10 (antisense) of *prp-8*. The *rr40* mutation is indicated by a vertical arrow. (B) Species of cDNA of varying sizes were excised from 2% agarose gels and subjected to sequence analysis (left). The sequences indicated that animals mutant for *prp-8(rr40)* possess wild-type and at least two aberrant forms of *prp-8* mRNA, while only the wild-type *prp-8* sequence was detected in both wild-type and *cdc-25.1(rr31)* animals. Schematic representations of the three mRNA species obtained from the *prp-8(rr40)* mutants are depicted on the right. Mature mRNA containing full or partial intron inclusions encode premature stop codons (arrowhead) followed by a frameshift. Uppercase letters correspond to exon sequence, lowercase letters represent intron 8. The *rr40* G7337A substitution (vertical arrow) is underlined in the sequences. The nucleotides highlighted in bold represent the first stop codon encoded in the aberrant *prp-8* mRNAs and the horizontal bars indicate the detected splice sites. The intron between exons 9 and 10 was correctly spliced in all mRNA species. Note that compromising the NMD pathway increases the level of aberrant *prp-8(rr40)* mRNA. (C) The translation of both aberrant *prp-8(rr40)* mRNAs is predicted to result in a truncated PRP-8(*rr40*) protein that lacks the C-terminal-most 138 amino acids (underlined *C. elegans* sequence after the STOP [vertical arrow]). The crystal structure of the peptide encompassing the N-terminal extension (N), the MPN domain and the C-terminal extension (C) was resolved for *C. elegans* PRP-8 (Zhang et al. 2007). The *rr40*-mediated truncation removes half of the PRP-8 MPN interacting domain and the entire C-terminal extension. The corresponding, highly conserved human hPrp8 sequence is represented underneath, with all hPrp8 mutations associated with human autosomal dominant retinitis pigmentosa RP13 (boxed and underlined residues represent substitution and frameshift mutations, respectively).

prp-8 mRNA from *prp-8(rr40)* mutants formed a slightly broader and more diffuse molecular weight band, the levels of which were reduced approximately twofold compared with control *prp-8* levels, consistent with the semi-quantitative RT-PCR results (Fig. 6A, top; data not shown).

To test whether the aberrant *prp-8* transcripts are recognized and subsequently eliminated by NMD, we performed semiquantitative RT-PCR of *prp-8* between exon 8 and exon 10 in *prp-8(rr40); smg-1(r861)* mutants that cannot elicit the NMD pathway (Hodgkin et al. 1989). While the levels of the *prp-8* wild-type variant appear unaffected, blocking the NMD pathway consistently increased the population of aberrant *prp-8(rr40)* mRNA that retained the entire intron (Fig. 5B). Since a significant amount of aberrantly spliced mRNA was still detectable in *prp-8(rr40)* mutants with functional NMD pathways (Fig. 5B), we propose that these PTC-containing messages can only partially elicit a NMD response.

prp-8(rr40) affects the levels of maternal mRNA in an NMD-independent manner

PRP-8 has a highly conserved role in the formation and the catalysis of the spliceosomal complexes; thus, we reasoned that reduced levels of endogenous wild-type PRP-8 could potentially affect the splicing efficiency of every pre-mRNA. To test this possibility, we examined the mRNA levels of a number of representative transcripts by Northern analysis, including five maternally provided transcripts (*oma-1*, *pie-1*, *cye-1*, *cdc-25.1*, and *lag-1*) in addition to two zygotically transcribed messages (*act-1* and *elt-2*). Surprisingly, only the maternally provided mRNA levels were reduced in *prp-8(rr40)* mutants, while the levels of the zygotically expressed transcripts were comparable to that of the control animals and were unaffected by the *prp-8(rr40)* mutation (Fig. 6A). These results were reproduced independently by semiquantitative RT-PCR for both endogenous and transgenic transcripts in various genetic backgrounds (Fig. 6B,C), confirming the differential sensitivity to *prp-8(rr40)* between maternal and zygotic transcripts.

To determine whether the reduction in maternal mRNA levels was due to splicing defects that would result in the NMD of incorrectly or unspliced pre-mRNA, we performed semiquantitative RT-PCR of these transcripts in *smg-1(r861); prp-8(rr40)* double mutants. Similar to what we found in *prp-8(rr40)*, single RT-PCR products were detected in *smg-1(r861); prp-8(rr40)* for all maternal and zygotic transcripts tested (except for *prp-8* itself), corresponding to the expected sizes for each properly spliced mRNA (Fig. 6B,C). These data suggest that splicing per se is functional in *prp-8(rr40)* mutants and that the observed decrease in the maternal mRNAs occurs independently of the NMD pathway.

FIGURE 6. *prp-8(rr40)* reduces the levels of *prp-8* and other maternal mRNA transcripts, without affecting zygotic transcripts. (A) Quantitative Northern analysis of the indicated mRNA performed on wild-type, *cdc-25.1(rr31)*, and *cdc-25.1(rr31); prp-8(rr40)* animals. Wild-type and *cdc-25.1(rr31)* control animals show little variation in their mRNA levels, while *prp-8* levels (top) and the levels of five other maternally provided transcripts (*cdc-25.1*, *lag-1*, *cye-1*, *oma-1*, *pie-1*) are substantially reduced in *cdc-25.1(rr31); prp-8(rr40)* suppressors compared with the rRNA loading controls and the zygotically transcribed actin (*act-1*) and endodermal-specific GATA factor (*elt-2*) genes. (B) Representative semiquantitative RT-PCRs performed on AZ244 and JH1327 animals (first and third column, respectively; see Materials and Methods for complete genotypes). These transgenic animals possess different full-length genomic, intron-containing GFP constructs exclusively in their germ line (*pie-1* promoter). Both the endogenous and transgenic maternal mRNA levels are reduced in a *prp-8(rr40)* mutant background (second and last column, respectively), while the zygotic *act-1* and *elt-2* messages seem unaffected. (C) The *prp-8(rr40)*-associated reduction in maternal mRNA levels (*cdc-25.1*, *pie-1*, and *oma-1*) does not depend on the NMD of unspliced pre-mRNAs, as single RT-PCR amplicons corresponding to correctly spliced mRNAs are produced in the *smg-1(r861); prp-8(rr40)* double mutant, with the exception of *prp-8(rr40)*. Every primer set encompasses one or multiple genomic introns. Representative semiquantitative RT-PCR products indicate that compromise of the NMD pathway modestly decreases the levels of the maternal mRNAs, while the levels of zygotically expressed transcripts (*act-1*, *elt-2*, *end-3*, and *lin-23*) are more stable. Note that *lin-23* is contributed both maternally and zygotically.

To assess whether the spectrum of phenotypes associated with *prp-8(rr40)* are due exclusively to the decreased levels of functional full-length PRP-8, or if the truncated *prp-8(rr40)* gene products may contribute to these defects, potentially in a dominant-negative manner, we analyzed the degree of the *cdc-25.1(rr31)*-dependent intestinal hyperplasia in *cdc-25.1(rr31); prp-8(rr40)*; *smg-1(RNAi)* animals, in which the truncated forms of *prp-8* are more abundant (Fig. 5B). The RNAi-mediated knockdown of *smg-1* had a minimal effect on the intestinal cell numbers observed in *cdc-25.1(rr31); prp-8(rr40)* hatchlings (27.5 ± 5.5 [$n = 64$] in *cdc-25.1(rr31); prp-8(rr40)*; *smg-1(RNAi)* animals versus 25.8 ± 5.3 [$n = 80$] in *cdc-25.1(rr31); prp-8(rr40)*), suggesting that loss of the NMD pathway does not significantly modify the *prp-8(rr40)*-associated suppression of the intestinal hyperplasia. The intestinal cell counts in both *smg-1(r861)* and wild-type animals subjected to *smg-1(RNAi)* looked completely wild type (20 intestinal cells). In addition, we also quantified the penetrance of the *prp-8(rr40)*-associated Emb and Him

phenotypes in *smg-1(r861); prp-8(rr40)* double mutants (31% Emb, $n = 1425$ and 8.4% Him, $n = 986$) and found that they were only marginally enhanced compared with *prp-8(rr40)* single mutants (26% Emb, $n = 2837$ and 5.3% Him, $n = 747$), while the frequency of Emb and Him phenotypes in control *smg-1(r861)* were essentially indistinguishable from wild-type animals (Emb, 1.2%, $n = 1870$, and 0.8% Him, $n = 1848$). Thus, it seems that the truncated variant of PRP-8(*rr40*) does not appear to act dominant negatively when permitted to accumulate in a Smg background, as it does not significantly contribute to the *prp-8(rr40)*-associated defects. However, since blocking the NMD pathway in *prp-8(rr40)* mutants reduced the levels of maternal mRNAs, albeit only marginally (compare second and last column in Fig. 6C), we cannot formally exclude that the truncated PRP-8(*rr40*) protein is also capable of assembling into the spliceosome, which might consequently reduce its efficiency.

Taken together, we found that maternally loaded transcripts are very sensitive to the *prp-8(rr40)* mutation, while the levels of the zygotic transcripts appear less perturbed by these changes. Moreover, the decline in maternal mRNAs was not dependent on NMD of unspliced pre-mRNA. Our results imply that the low level of wild-type

PRP-8 protein synthesized in *prp-8(rr40)* mutants meets or surpasses a functional threshold that is sufficient for the splicing of pre-mRNAs, allowing most of these animals to survive, while the truncated *prp-8(rr40)* gene products contribute only minimally, if at all, to the various *prp-8(rr40)*-associated phenotypic traits.

Low PRP-8 levels suppress a second maternal effect gain-of-function mutation

To determine whether the *prp-8(rr40)*-associated differences in maternally loaded mRNA levels were physiologically relevant, we investigated whether reduced levels of PRP-8 could affect a previously characterized mutation in *oma-1*, an essential maternal gene that coordinates maternal protein degradation during early embryogenesis (Lin 2003). OMA-1 becomes phosphorylated by MBK-2, which is required both for its activation in the one-cell embryo and its subsequent degradation after the first mitosis (Lin

2003; Nishi and Lin 2005; Shirayama et al. 2006; Stitzel et al. 2006). *oma-1(zu405)* is a gain-of-function mutant, wherein its *mbk-2*-dependent destruction site becomes stabilized, similar to what occurs with the CDC-25.1(*rr31*) protein (Kostic and Roy 2002; Nishi and Lin 2005). This perturbation in OMA-1(*zu405*) destabilization affects the timely degradation of PIE-1, POS-1, MEX-1, MEX-5, and SKN-1 among others, causing these maternal factors to perdure, triggering embryonic arrest (Lin 2003; Shirayama et al. 2006).

If PRP-8 plays a general role in maintaining adequate levels of maternal transcripts, then *prp-8(rr40)* or *prp-8*(RNAi) should reduce the levels of the proteins stabilized in *oma-1(zu405)* and attenuate the severity of its embryonic lethal phenotype. Consistent with this, we found that a reduction in *prp-8* expression levels reproducibly increased the number of viable embryos in the *oma-1(zu405)*; *prp-8(rr40)* double mutants (threefold), while *oma-1(zu405)*; *prp-8* (hypomorphic RNAi) resulted in a 50-fold increase in the number of survivors compared with *oma-1(zu405)* animals fed on control *gfp*(RNAi)-inducing bacteria (Table 1).

Therefore, the reduction in *prp-8* expression levels suppresses another stabilizing maternal-effect *gf* mutation, lending further genetic support for an important role of PRP-8 in the germ line in maintaining the levels of maternally provided transcripts.

Only a subset of splicing factors comprising U2- and U5-specific snRNPs suppress the *cdc-25.1(gf)* embryonic phenotype

Because of the essential role PRP-8 plays in the spliceosomal reactions and based on our previous results, it is plausible that limiting PRP-8 activity would mainly affect maternal mRNA levels through affecting overall splicing efficiency.

To determine whether a general reduction of splicing activity may account for our findings, we tested whether decreasing the expression levels of other splicing components by RNAi would suppress the *cdc-25.1(rr31)*-associated

intestinal hyperplasia in a manner similar to *prp-8(rr40)* or *prp-8*(RNAi). A total of 81 dsRNA-expressing RNAi clones, all representing genes implicated in the splicing process or associated splicing events were fed to *cdc-25.1(rr31)* animals (Table 2). Surprisingly, only a subset of the clones that induce embryonic lethality as a terminal phenotype gave rise to significant and reproducible suppression of the *cdc-25.1(rr31)*-associated cell cycle defect. These genes corresponded to essential spliceosomal components and were primarily members of the U2- and U5-specific snRNP proteins, or components of the PRP19 complex, which is also transiently associated with the U5 snRNP in a larger 35S complex (Makarov et al. 2002; Table 2).

That the compromise of other splicing components also suppresses the *cdc-25.1(rr31)*-associated intestinal hyperplasia is consistent with PRP-8(*rr40*) triggering its effects through reducing spliceosomal efficiency. However, only a limited subset of the essential splicing factors tested, namely, those associated with U2, U5, and/or PRP19, are capable of altering the intestinal hyperplasia of *cdc-25.1(rr31)* mutants like *prp-8(rr40)*, suggesting that in *C. elegans* these factors/complexes may play specialized and limiting roles in regulating spliceosome efficiency in a tissue/germ-line-specific manner.

DISCUSSION

The early developmental program of *C. elegans* is tightly regulated by gene products that are expressed within the maternal germ line. The expression levels of such genes would be expected to be very high in order to support the developmental events that unravel during embryogenesis, while the localization, activity, and degradation of these gene products has to be tightly regulated and coordinated with the emerging zygotic gene-expression program. The isolation of a strict maternal effect gain-of-function mutation in *cdc-25.1* that triggers tissue-specific embryonic hyperplasia by interfering with the timely proteolysis of the CDC-25.1(*gf*) phosphatase indicates that the regulation of the early embryonic cell divisions can be perturbed by changes in the levels of crucial maternal factors. The importance of Cdc25A expression and degradation during animal development prompted us to look for genes that would regulate the levels of this phosphatase, using suppression of the *cdc-25.1(gf)*-associated intestinal hyperplasia as a readout. With this strategy, we identified unexpected tissue-specific maternal roles for the general splicing factor *prp-8*.

prp-8(rr40) causes incomplete cryptic splicing, decreasing its own expression level

We found that the *prp-8(rr40)* allele contains a mutant donor splice site, which induces cryptic splicing and affects

TABLE 1. Reduced PRP-8 levels suppress *oma-1(zu405)gf*

Genotype	Survival (%)
<i>prp-8(rr40)</i>	74 (n = 2837)
<i>oma-1(zu405)</i>	0.6 ± 0.4 (n = 3490)
<i>oma-1(zu405); prp-8(rr40)</i>	1.8 ± 2.28 (n = 666)
<i>prp-8</i> (RNAi) ^a	20 (n = 1233)
<i>oma-1(zu405); gfp</i> (RNAi) ^a	0.3 ± 0.5 (n = 1076)
<i>oma-1(zu405); prp-8</i> (RNAi) ^a	12.2 ± 3.2 (n = 466)

^aHypomorphic RNAi was performed as described in Supplemental Figure S1. L4 larvae were fed for 24 h on bacteria expressing dsRNA corresponding to the indicated gene before being transferred to non-RNAi plates, on which the total progeny was scored for survival.

TABLE 2. A distinct subset of splicing factors suppresses the *cdc-25.1(rr31)*-associated hyperplasia

<i>C. elegans</i> (cosmid name)	<i>S. cerevisiae</i>	<i>H. sapiens</i>	RNAi phenotype	
			Terminal ^a	Intestinal ^b
Core Sm and Lsm proteins				
<i>snr-1</i> (Y116A8C.42)	Smd3	SmD3	Emb, Sck	Extra cells
<i>snr-2</i> (W08E3.1)	Smb1	SmB/B'	Emb	Extra cells
<i>snr-3</i> (T28D9.10)	Smd1	SmD1	Emb, Sck	Extra cells
<i>snr-4</i> (C52E4.3)	Smd2	SmD2	Emb, Sck	Extra cells
<i>snr-5</i> (ZK652.1)	Smx3	SmF	Emb, Sck	Extra cells
<i>snr-6</i> (Y49E10.15)	Sme1	SmE	Emb	Extra cells
<i>snr-7</i> (Y71F9B.4)	Smx2	SmG	Emb, Sck	Extra cells
<i>gut-2</i> (T10G3.6)	Lsm2	LSm2	Sck, Gro	Extra cells
<i>lsm-6</i> (Y71G12B.14)	Lsm6	LSm6	Emb, Sck	Extra cells
<i>lsm-7</i> (ZK593.7)	Lsm7	LSm7	Emb	Extra cells
U1 snRNP and related proteins				
ZK1098.1	Prp40	FBP11	WT	Extra cells
<i>rnp-2</i> (K08D10.4)	Mud1	U1-A	WT	Extra cells
<i>rnp-3</i> (K08D10.3)	Mud1	U1-A	WT	Extra cells
<i>rnp-2</i> + <i>rnp-3</i>	Mud1	U1-A	WT	Extra cells
F08B4.7	Yhc1	U1-C	WT	Extra cells
<i>sfa-1</i> (Y116A8C.32)	Msl5	SF1	WT	Extra cells
U2 snRNP				
<i>sap-1</i> (H20J04.8)	Lea1	U2-A'	WT	Extra cells
T13H5.4	Prp9	SF3a60	Emb	± Suppressed
F11A10.2	Prp11	SF3a66	Emb	Extra cells
<i>prp-21</i> (W07E6.4)	Prp21	SF3a120	Emb, Sck	Extra cells
<i>sap-49</i> (C08b11.5)	Hsh49	SF3b49	Emb	Extra cells
<i>tag-203</i> (K02F2.3)	Rse1	SF3b130	Emb	Suppressed
T08A11.2	Hsh155	SF3b155	Emb	Suppressed
U2 snRNP-related				
<i>uaf-2</i> Y116A8C.35	—	U2AF35	Emb	Extra cells
F56D2.6	Prp43	hPRP43	Emb	Extra cells
U4/U6 snRNP				
Y110A7A.8	Prp31	PRP31	Emb	Suppressed
M03C11.7	Prp3	hPRP3	Emb	Extra cells
<i>prp-4</i> (F22D6.5)	Prp4	hPRP4	WT	Extra cells
<i>cyn-11</i> (T01B7.4)	Cpr1	USA-Cyp	WT	Extra cells
M28.5	Snu13	15.5 tri-snRNP	Emb	Extra cells
U4/U6●U5 tri-snRNP				
F19F10.9	Snu66	SART1	Emb	Extra cells
F09D1.1	Sad1	USP39	Emb, Sck	Extra cells
D1054.14	Prp38	hPRP38	Emb, Ste	Extra cells
<i>stip-1</i> (C07E3.1)	Spp382	TFIP11	Emb, Sck	Extra cells
U5 snRNP				
<i>prp-8</i> (C50C3.6)	Prp8	U5-220 kDa/hPrp8	Emb, Ste	Suppressed
Y46G5A.4	Brr2	U5-200 kDa	Emb	Suppressed
<i>eft-1</i> (ZK328.2)	Snu114	U5-116 kDa	Emb, Ste	Suppressed
Y59A8B.6	Prp6	U5-102 kDa	WT	Extra cells
F01F1.7	Prp28	U5-100 kDa	Emb	Extra cells
C18E3.5	—	U5-40 kDa	WT	Extra cells
F08G12.2	—	U5-40 kDa	WT	Extra cells
Prp19/CDC5L complex and related proteins				
T10F2.4	Prp19	PRP19	Emb, Ste	Suppressed
<i>phi-7</i> (D1081.8)	Cef1	CDC5L	Emb	Extra cells
<i>tag-135</i> (D1054.15)	Prp46	PRL1	Emb	Extra cells
F53B7.3	Isy1	hISY1	Emb	± Suppressed
C50F2.3	Syf1	hSYF1	Emb	± Suppressed
K04G7.11	Syf2	P29	WT	Extra cells
M03F8.3	Syf3	hSYF3/CRN	Emb, Ste	± Suppressed
<i>skp-1</i> (T27F2.1)	Prp45	SKIP	Emb, Sck	Extra cells
<i>emb-4</i> (Y80D3A.2)	—	AQR	Emb	Extra cells

(continued)

TABLE 2. Continued

<i>C. elegans</i> (cosmid name)	<i>S. cerevisiae</i>	<i>H. sapiens</i>	RNAi phenotype	
			Terminal ^a	Intestinal ^b
C07A9.2	Bud31	G10	Emb, Ste	Extra cells
T12A2.7	—	BCAS2	Emb, Ste	Extra cells
Protein recruited to A-complex				
Y55F3AM.3	—	RBM39	WT	Extra cells
<i>exc-7</i> (F35H8.5)	—	ELAV-like 1	WT	Extra cells
Protein recruited to B-complex				
<i>let-858</i> (F33A8.1)	Cwc22	KIAA1604	Emb	Suppressed
<i>mog-4</i> (C04H5.6)	Prp2	hPRP2	Emb, Gro	Extra cells
F43G9.10	—	MFAP1	Emb	Extra cells
<i>pab-1</i> (Y106G6H.2)	Pab1	PABP1	Gro, Ste	Extra cells
<i>mtr-4</i> (W08D2.7)	Mtr4	SKIV2L2	Gro	Extra cells
<i>pabp-2</i> (C17E4.5)	—	PABPN1	Emb, Ste	Extra cells
<i>ubl-5</i> (F46F11.4)	Hub1	UBL5	WT	Extra cells
Step 2 factors				
<i>mog-1</i> (K03H1.2)	Prp16	PRP16	Emb	Extra cells
F49D11.1	Prp17	PRP17	Emb	Extra cells
F32B6.3	Prp18	PRP18	WT	Extra cells
<i>mog-5</i> (EEED8.5)	Prp22	PRP22	Emb	Extra cells
K07C5.6	Slu7	SLU7	Emb	Extra cells
Protein recruited to C-complex				
<i>rack-1</i> (K04D7.1)	Asc1	RACK1	Emb, Gro	Extra cells
<i>ruvb-1</i> (C27H6.2)	Rvb1	TIP49	Emb, Gro	Extra cells
R07E5.1	—	GPATCH1	Lvl, Sck	Extra cells
<i>cacn-1</i> (W03H9.4)	—	c19orf29	Emb	Extra cells
Exon junction complex components				
<i>mp-5</i> (K02F3.11)	—	RNPS1	WT	Extra cells
<i>mp-4</i> (R07E5.14)	—	Y14/TSUNAGI	Emb	Extra cells
<i>mag-1</i> (R09B3.5)	—	MAGOH	Emb, Gro	Extra cells
C16C10.4	—	SAP18	WT	Extra cells
SR proteins				
<i>rsp-2</i> (W02B12.2)	—	SRp75	WT	Extra cells
<i>rsp-3</i> (Y111B2A.18)	—	SF2/ASF	Emb	Extra cells
<i>rsp-4</i> (EEED8.7)	—	SC35	WT	Extra cells
<i>rsp-6</i> (C33H5.12)	—	9G8	WT	Extra cells
SR-related				
<i>rsr-1</i> (F28D9.1)	—	SRm160	WT	Extra cells
<i>rsr-2</i> (Y57A10A.21)	—	SRm300	WT	Extra cells
hnRNP				
<i>hrp-1</i> (F42A6.7)	—	hn RNP A3	Gro, Sck	Extra cells
<i>ztf-4</i> (T10B11.3)	—	hnRNP C	WT	Extra cells

Phenotypic classification: An “Extra cells” intestinal RNAi phenotype refers to animals displaying typical *cdc-25.1(rr31)*-associated hyperplasia (~41 intestinal cells at hatching), without any suppression. A “suppressed” intestinal phenotype refers to penetrant suppression of the hyperplasia (>80% of the animals display wild-type intestine), while “± suppressed” indicates that only some animals (<10%) executed wild-type intestinal divisions, which is never seen in *cdc-25.1(rr31)*. (Emb) Embryonic lethality; (Sck) sick; (Gro) growth defect; (Ste) sterile adult; (WT) wild-type morphology. *n* > 200 for every RNAi. Spliceosomal components were classified after Deckert et al. (2006), Behzadnia et al. (2007), and Bessonov et al. (2008).

^aStandard RNAi treatment.

^bHypomorphic RNAi treatment (see Materials and Methods and Supplemental Fig. S1).

the efficient removal of the affected intron. In *prp-8(rr40)* mutants, wild-type *prp-8* transcripts are detectable but at reduced levels, while the additional *prp-8* mRNA variants that are generated are partially eliminated by NMD.

This incomplete targeting of the *prp-8(rr40)* PTC by the NMD is likely due to the positional effect that has been described for NMD response in *C. elegans*. Unlike in

mammals, PTC recognition seems to be independent of the formation of a downstream exon junction complex (EJC) at splice site boundaries, but mainly dependent on the distance of the PTCs from the natural 3' end of the transcript (Longman et al. 2007). Consistent with this, the partial NMD response associated with aberrant *prp-8(rr40)* transcripts may reflect the close proximity of their PTCs to

the natural stop, similar to what has been reported for other incompletely degraded PTC-containing transcripts (Dibb et al. 1985; Bejsovec and Anderson 1988; Longman et al. 2007).

On the other hand, the ability of the spliceosome to recognize and properly process unconventional AU or UU donor splice sites, as detected in *prp-8(rr40)* mRNAs, has already been noticed in other *C. elegans* splice site mutants (Aroian et al. 1993; Rushforth and Anderson 1996). This phenomenon reveals the intriguing plasticity of the spliceosomal macrocomplex in identifying splice site boundaries and indicates that the information required in *cis* to mark the splice site boundaries is not exclusively encrypted in the highly conserved donor and acceptor sequences.

PRP-8 plays a predominant role in the germ line

In *C. elegans*, the germ line represents the only tissue with sustained cell division and growth, enabling germ cells to proliferate after every somatic cell division is terminated. Furthermore, cellularization ensures that oocytes are loaded with the maternal factors required for oogenesis and early embryonic development. We show that the mRNA levels of transcripts that are expressed in the maternal germ line are reduced in an NMD-independent manner when wild-type PRP-8 levels are reduced by *rr40*, while the levels of zygotically transcribed messages seem less affected. This phenomenon highlights an intrinsic difference in the splicing and/or expression requirement between the germ line and the somatic tissues in *C. elegans*. High levels of functional PRP-8 protein are likely necessary in the germ line to support its important splicing requirement, and thus, a reduction in PRP-8 levels below a critical threshold would predominantly affect mechanisms that rely on maternal factors. Consistent with this, the maternal effect of the *prp-8(rr40)* mutation, its associated Ste and Emb phenotypes, together with its temperature-sensitive period and its effect on *cdc-25.1(rr31)* and *oma-1(zu405)*, all pinpoint toward a significant role for PRP-8 in the germ line. Remarkably, available in situ hybridization data indicates that *prp-8* is almost exclusively expressed in the germ line, with almost no detectable signal in the somatic tissues (<http://nematode.lab.nig.ac.jp/db2/ShowGeneInfo.php?celk=CELK00510>).

It is surprising that a gene product presumed to be required in all cells for the splicing of every transcript would be restricted to the germ line of an organism. Thus, it seems most likely that *prp-8* is abundantly expressed in the developing germ line to enable the high splicing requirement of maternal transcripts in early embryos, and that later on, this maternal *prp-8* contribution (in the form of stable mRNA and/or protein) and possibly limited zygotic *prp-8* expression, would suffice for the lower splicing requirement necessary for the limited and periodic developmental pulses of zygotic expression. Consistent with

the important requirement for RNA metabolism in the germ line and early embryos, maternal transcripts corresponding to genes involved in splicing (including *prp8*) and translation were enriched in *Drosophila* embryos and detected to be the most stable of all mRNA (Lecuyer et al. 2007).

Only a subset of splicing factors suppress intestinal hyperplasia

By using the feeding RNAi library, we noticed that only a subset of the 81 tested splicing factors was able to suppress the *cdc-25.1(rr31)*-associated hyperplasia (Table 2). Surprisingly, essential splicing factors like the U1 to U5 core snRNP components *snr-1* to *snr-7* that give rise to complete embryonic lethality as a terminal phenotype did not show any suppression of the hyperplasia following RNAi treatment. Since our feeding RNAi protocol guarantees a reproducible RNAi effect by triggering the strongest viable hypomorphic phenotype possible for any clone resulting in 100% lethality (Supplemental Fig. S1; Materials and Methods), this result suggests that a general reduction of splicing efficiency cannot fully account for the observed suppression.

The suppressors reported in Table 2 correspond mainly to members of the U2 snRNP, U5 snRNP, or associated factors thereof, like the Prp19 complex (NTC) members that transiently associate with U5 proteins (Makarov et al. 2002). Intriguingly, the C-terminal fragment that is deleted in the truncated variants of PRP-8(*rr40*) corresponds to a protein-interaction domain that enables interaction with its own N-terminal domain and with at least two other U5-specific splicing factors, namely Br2 and Snu114 (Pena et al. 2007; Zhang et al. 2007). Remarkably, we found that RNAi-mediated knockdown of their *C. elegans* orthologs completely suppressed the *cdc-25.1(rr31)*-associated hyperplasia, similar to *prp-8* (Table 2). Consistent with the high homology of Prp8 proteins between species, both at the molecular and functional levels, it is very likely that *C. elegans* PRP-8 also interacts with these factors through its C-terminal domain to form a multisubunit complex. We suggest that the factors that suppress the *cdc-25.1(rr31)*-associated hyperplasia represent a specific class of spliceosomal components, the function and/or level of which may be particularly important in the *C. elegans* germ line to regulate the levels of mature maternal mRNAs that have to be loaded into the developing oocytes to control embryonic cell division cycles, in addition to other developmental processes.

Links between splicing events and cell cycle regulation

Links between splicing events and cell cycle regulation that involve Prp8 and other splicing components have been

reported in budding and fission yeast, while in *Drosophila*, orthologs of the splicing factors that suppress *cdc-25.1(rr31)* affect cell growth, supporting the idea that the links between splicing and cell cycle control may have been conserved from yeast to higher eukaryotes (Shea et al. 1994; Lundgren et al. 1996; Potashkin et al. 1998; Ben-Yehuda et al. 2000a,b; Russell et al. 2000; Habara et al. 2001; Coelho et al. 2005).

It seems unlikely that PRP-8 [or the other *cdc-25.1(rr31)* suppressors] plays any kind of direct role in cell cycle regulation, mainly because of the pleiotropic phenotypes associated with *prp-8(rr40)*. Consistent with this, recent reports provide growing evidence that in yeast, the cell cycle phenotypes arise through splicing-dependent mechanisms that indirectly affect the expression of proteins involved in the regulation of cell cycle and/or growth (Burns et al. 2002; Dahan and Kupiec 2002, 2004; Rasheva et al. 2006; Kaplan and Kupiec 2007). Since compromise of maternal *cdc-25.1* or *cye-1* (cyclin E) can suppress the *cdc-25.1(rr31)*-associated hyperplasia (Kostic and Roy 2002), it is more plausible that the *prp-8(rr40)*-mediated suppression is caused, at least in part, by the reduction of these two important maternally contributed cell cycle regulators, the levels of which would become limiting for the supernumerary intestinal divisions, resulting in a tissue-specific suppression of the hyperplasia.

Tissue-specific defects from mutations in general splicing factors

In metazoans, null mutations in spliceosomal components are most often embryonic lethal, owing to their essential functions at the cellular level. Interestingly, mutations that disrupt the assembly or function of snRNPs have been associated with several tissue-specific diseases in humans (Faustino and Cooper 2003). Haploinsufficient and/or dominant-negative mutations in human hPrp8, along with mutations in three other general and ubiquitous splicing factors (hPrp31, hPrp3, and Pap1) involved in the formation of U4/U6-U5 tri-snRNP (Makarova et al. 2002), have been linked with various forms of the hereditary autosomal dominant retinal-specific disorder retinitis pigmentosa (McKie et al. 2001; Vithana et al. 2001; Chakarova et al. 2002; Maita et al. 2004, 2005). This neurodegenerative syndrome causes severe visual impairment as a consequence of photoreceptor apoptosis and eventually leads to other pathological symptoms in the retina that often result in complete blindness (Kennan et al. 2005; Mordes et al. 2006). Remarkably, all hPrp8 mutations that give rise to retinitis pigmentosa (RP13) affect residues concentrated within its last exon at the end of the hPrp8 C-terminal binding domain (Fig. 5C) (Grainger and Beggs 2005). A hPrp8 fragment lacking these residues completely failed to interact with its N terminus domain, with hBrr2 or hSnu114 (Pena et al. 2007), while these interactions were

altered in yeast Prp8p variants that mimicked RP13 point mutations (Boon et al. 2007). The resulting splicing efficiency decrease due to impairment in protein–protein interactions together with a possible disruption in the structure or folding kinetics of the C-terminal binding domain are believed to underlie the molecular basis of the RP13 disorder, but the reasons for the associated retinal-specific phenotype still remain controversial (Boon et al. 2007; Pena et al. 2007; Zhang et al. 2007).

We report here that the residues mutated in RP13 are missing from the corresponding *C. elegans* PRP-8(*rr40*) variants that retain intronic sequences (Fig. 5C), while loss of function in the ortholog of hPrp31, which triggers RP11 due to haploinsufficiency (Rio Frio et al. 2008) similarly suppresses the intestinal hyperplasia in our RNAi assay (Table 2). hPrp3 triggers RP most probably in a dominant-negative manner (Gonzalez-Santos et al. 2008), and loss-of-function in its *C. elegans* ortholog did not suppress *cdc-25.1(rr31)*.

The differential sensitivity to a mutation in a general component of the spliceosome between tissues of a same organism indicates that the intrinsic nature and dynamics of a given tissue play a major role in the expressivity of a phenotypic trait. Since the retina constitutes a tissue with sustained expression of genes and high turnover of proteins (especially rhodopsin) involved in maintaining the light-sensitive properties of its photoreceptors, it has been proposed that a general reduction in expression would primarily affect this type of tissue (Kennan et al. 2005). Thus, it appears that metabolically active tissues like the human retina, or the *C. elegans* germ line, are more susceptible than others when the splicing efficiency of crucial components drops below a threshold, because the cells constituting these specialized tissues rely on high expression levels to efficiently execute their respective physiological functions. The striking parallels that exist between the gene identities, the molecular lesions, the effects of dosage, and the tissue-specific effects seen in the phenotypes of hPrp8/hPrp31-linked retinitis pigmentosa and the *prp-8(rr40)*-associated germ-line defect suggest that this model may provide molecular insight as to how these mutations manifest in a single tissue.

MATERIALS AND METHODS

Strains

All *C. elegans* strains were cultured at 20°C according to standard procedures unless stated otherwise (Brenner 1974). The following strains, rearrangements, and transgenes were used: wild-type Bristol (N2); Hawaiian ecotype CB4856 (Hodgkin and Doniach 1997). MR156 *rrIs01[elt-2::GFP; unc-119(+)]*. MR142 *cdc-25.1(rr31); rrIs01*. MR183 *cdc-25.1(rr31rr36); rrIs01*. MR184 *cdc-25.1(rr31); rr37; rrIs01*. MR185 *cdc-25.1(rr31); rr38; rrIs01*. MR186 *cdc-25.1(rr31); rr39; rrIs01*. MR187 *cdc-25.1(rr31); rr40; rrIs01*. MR246 *rrEx17[elt-2::GFP]* in CB4856. MR320 *cdc-25.1(rr31);*

*lon-1(e1137) unc-32(e189); rrls01. MR372 cdc-25.1(rr31); unc-32(e189) sma-3(e491); rrls01. MR475 cdc-25.1(rr31); sma-3(e491) unc-36(e251); rrls01. MR375 cdc-25.1(rr31) unc-13(e450); lon-1(e1137) rrl40; rrls01. MR349 cdc-25.1(ij48); rrls01. MR396 cdc-25.1(ij48); lon-1(e1137) rrl40; rrls01. MR625 smg-1(r861); rrl40; rrls01. TR1331 smg-1(r861). JR2274 wls137(end-3::END-3[P202L)::GFP; pRF4) (gift from M. Maduro, University of California Riverside). AZ244 *unc-119(ed3); ruls57([pAZ147: pie-1 promoter/β-tubulin::GFP; unc-119(+)])* (Praitis et al. 2001). JH1327 *axEx73(pJH3.92: pie-1 promoter/pie-1::GFP; rol-6(su1006))* (Reese et al. 2000). DP38 *unc-119(ed3). TX20 oma-1(zu405). BC4634 dpy-17(e164) sDf125 unc-32(e189); sDp3. BC4638 dpy-17(e164) sDf127(s2428) unc-32(e189); sDp3. BC4696 dpy-17(e164) sDf128(s2786) unc-32(e189); sDp3. BC4677 dpy-17(e164) sDf135(s2767) unc-32(e189); sDp3. CX2914 *nDf16/dpy-17(e164) unc-32(e189). MT3022 nDf20/sma-2(e502) unc-32(e189).***

Semiclonal screen for maternal-effect suppressors of *cdc-25.1(rr31)*

MR142 *cdc-25.1(rr31); rrls01* animals were mutagenized at the L4 stage with 40 mM ethylmethanesulfonate (EMS) as previously described (Brenner 1974). Mutagenized worms were transferred to 100-mm plates (30–40 per plate) and allowed to produce progeny. The L4 stage F₁ progeny were picked to 35-mm plates (two per plate). The gravid adult F₂ progeny were washed off half of each plate, pooled, subjected to alkaline/hypochlorite, and the resultant F₃ generation was synchronized at the L1 stage. F₃ animals were grown to the L4 stage and screened under a fluorescent dissecting microscope for suppression of the *cdc-25.1(rr31)*-associated supernumerary divisions. Candidate mutants were singled and their progeny re-evaluated. A total of 5456 haploid genomes were analyzed and five suppressors were isolated.

Mapping and cloning of *rr40*

MR187 *cdc-25.1(rr31); rrl40; rrls01* hermaphrodites were first crossed with Hawaiian CB4856 males carrying an extrachromosomal *rrEx17(elt-2::gfp)* transgene to allow for efficient visualization of the intestinal lineage in the cross progeny. A total of 75 suppressed F₂ and 75 nonsuppressed F₂ adults were isolated and lysed, and SNP-snp mapping using bulk segregant analysis was performed on the respective pools (Wicks et al. 2001), placing *rr40* in the middle of linkage group (LG) III. Subsequent deficiency and meiotic mapping refined the *rr40* locus between *sma-3* and *unc-36*, tightly linked and to the left of *unc-36*, between −0.396 and −0.355 map units. This 107-kb interval is covered by four cosmids and contains a total of 26 predicted genes. Systematic feeding RNAi of genes present in the mapping interval (Kamath et al. 2003) was then used to find candidates that would suppress the *cdc-25.1(rr31)*-associated hyperplasia and phenocopy the *rr40*-mediated suppression. Under standard RNAi conditions (see below), none of the clones tested suppressed *cdc-25.1(rr31)*, but four clones caused penetrant sterility (Ste) and 100% embryonic lethality (Emb). To test for their suppression potential, we developed a novel alternative feeding RNAi protocol that ensures the strongest viable hypomorphic phenotype possible for any given clone triggering complete Ste and/or Emb. Using this alternative RNAi strategy, one of the four clones consistently suppressed the *cdc-25.1(rr31)*-mediated hyperplasia. Independent

PCRs and sequencing analysis of this gene in *rr40* mutants revealed a single, EMS-typical base-pair substitution in *prp-8* (C50C3.6).

Standard and hypomorphic feeding RNAi

Standard feeding RNAi

Bacterial colonies from the feeding RNAi library were grown overnight at 37°C and dsRNA synthesis was induced on NGM plates containing 50 μg/μL ampicillin and 1 mM IPTG for 24 h at room temperature. L4 stage MR142 *cdc-25.1(rr31); rrls01* larvae were fed for 16 h on these plates and transferred for an additional day to a second RNAi plate, on which the progeny was scored for suppression of the *cdc-25.1(rr31)*-associated hyperplasia.

Hypomorphic feeding RNAi

dsRNA expression from bacteria containing the clones of interest was induced as described for standard feeding RNAi. L4 animals were allowed to feed on these RNAi plates for a precise and empirically determined period of time. This feeding period was determined as the one triggering the terminal Ste/Emb phenotype for around 24 h after the transfer of the animals from the RNAi plate to a non-RNAi standard nematode growing medium (NGM) plate seeded with OP50 bacteria, and typically varied from 8 to 30 h (Supplemental Fig. S1). Embryos laid by these transferred adults that eventually hatch possess minimal, but viable levels of the targeted gene product to survive embryogenesis, and can be scored for the strongest post-embryonic hypomorphic phenotypes. This protocol was successfully used to test the multiple lethal RNAi clones of the spliceosomal machinery (Table 2).

Lineage analysis

MR379 *wls137; rrls01* and MR380 *cdc-25.1(rr31); wls137; rrls01* were generated by crossing JR2274 hermaphrodites with MR142 males. MR389 *cdc-25.1(rr31); prp-8(rr40); wls137; rrls01* was generated by crossing MR380 hermaphrodites with MR187 males. Embryos were dissected from gravid MR379, MR380, or MR389 hermaphrodites and mounted on 2% agarose pads. The GFP expressed of the *end-3* promoter is visible from the E² (two intestinal cells) to the E⁸ stage (Maduro et al. 2005), while the *elt-2::gfp* marks intestinal nuclei from the E⁸ stage to adulthood (Fukushige et al. 1999). Intestinal cell divisions were monitored from the appearance of the intestinal precursor cell E onward using both DIC and epifluorescence.

RT-PCR and Northern blots

Total RNA was isolated from synchronized adults with a Trizol-based extraction method (Invitrogen). The RNA concentration was precisely quantified and adjusted to 200 μg/μL using a NanoDrop ND-1000 spectrophotometer. First-strand cDNA was performed on 1 mg of RNA using polydT primers and Expand Reverse Transcriptase (Roche) following the manufacturer's protocol. For each primer pair, parameters were optimized for semiquantitative RT-PCR (Marone et al. 2001). The cryptic splice sites and intron inclusions produced by the *prp-8(rr40)* mutation were detected by sequence analysis of the two bands detected in RT-PCRs (with polydT or sequence specific reverse primers)

across the *rr40* locus in MR187 animals and comparison with the current genomic *C. elegans* database accessible through Wormbase (www.wormbase.org).

DIG-labeled antisense RNA probes generated from *prp-8* [probe is complementary to a sequence present in all *prp-8(rr40)* variants], *cdc-25.1*, *cye-1*, *oma-1*, *pie-1*, *elt-2*, and *act-1* cDNA were used to perform Northern analysis on total RNA according to the manufacturer's protocol (Roche). Probes were detected chromogenically using NBT/BCIP. Detailed description of all primer sequences and/or cloning strategies are available upon request.

Microscopy and image processing

Light microscopy, image analysis, and processing were performed essentially as previously described (Kostic and Roy 2002).

SUPPLEMENTAL DATA

Supplemental material can be found at <http://www.rnajournal.org>.

ACKNOWLEDGMENTS

We thank all the members of the Roy laboratory, particularly Patrick Narbonne and Jimmy Ouellet for ideas and discussion. We are grateful to Rueyling Lin, Morris Maduro, and the *Caenorhabditis* Genetic Center, which is founded by the NIH National Center for Research Resources (NCRR), for *C. elegans* strains and reagents, and to the Kohara laboratory for making expression data available to the community. This work was supported by a Research Award from the Canadian Cancer Society. R.R. is a CIHR New Investigator.

Received May 6, 2008; accepted August 21, 2008.

REFERENCES

- Alphey, L., Jimenez, J., White-Cooper, H., Dawson, I., Nurse, P., and Glover, D.M. 1992. *twine*, a *cdc25* homolog that functions in the male and female germ line of *Drosophila*. *Cell* **69**: 977–988.
- Aroian, R.V., Levy, A.D., Koga, M., Ohshima, Y., Kramer, J.M., and Sternberg, P.W. 1993. Splicing in *Caenorhabditis elegans* does not require an AG at the 3' splice acceptor site. *Mol. Cell. Biol.* **13**: 626–637.
- Ashcroft, N. and Golden, A. 2002. CDC-25.1 regulates germ line proliferation in *Caenorhabditis elegans*. *Genesis* **33**: 1–7.
- Ashcroft, N.R., Kosinski, M.E., Wickramasinghe, D., Donovan, P.J., and Golden, A. 1998. The four *cdc25* genes from the nematode *Caenorhabditis elegans*. *Gene* **214**: 59–66.
- Bao, Z., Zhao, Z., Boyle, T.J., Murray, J.I., and Waterston, R.H. 2008. Control of cell cycle timing during *C. elegans* embryogenesis. *Dev. Biol.* **318**: 65–72.
- Behzadnia, N., Golas, M.M., Hartmuth, K., Sander, B., Kastner, B., Deckert, J., Dube, P., Will, C.L., Urlaub, H., Stark, H., et al. 2007. Composition and three-dimensional EM structure of double affinity-purified, human prespliceosomal A complexes. *EMBO J.* **26**: 1737–1748.
- Bejsovec, A. and Anderson, P. 1988. Myosin heavy-chain mutations that disrupt *Caenorhabditis elegans* thick filament assembly. *Genes & Dev.* **2**: 1307–1317.
- Ben-Yehuda, S., Dix, I., Russell, C.S., McGarvey, M., Beggs, J.D., and Kupiec, M. 2000a. Genetic and physical interactions between factors involved in both cell cycle progression and pre-mRNA splicing in *Saccharomyces cerevisiae*. *Genetics* **156**: 1503–1517.
- Ben-Yehuda, S., Russell, C.S., Dix, I., Beggs, J.D., and Kupiec, M. 2000b. Extensive genetic interactions between PRP8 and PRP17/CDC40, two yeast genes involved in pre-mRNA splicing and cell cycle progression. *Genetics* **154**: 61–71.
- Bessonov, S., Anokhina, M., Will, C.L., Urlaub, H., and Luhrmann, R. 2008. Isolation of an active step I spliceosome and composition of its RNP core. *Nature* **452**: 846–850.
- Boon, K.L., Grainger, R.J., Ehsani, P., Barrass, J.D., Auchynnikava, T., Inglehearn, C.F., and Beggs, J.D. 2007. *prp8* mutations that cause human retinitis pigmentosa lead to a U5 snRNP maturation defect in yeast. *Nat. Struct. Mol. Biol.* **14**: 1077–1083.
- Bowerman, B. 1998. Maternal control of pattern formation in early *Caenorhabditis elegans* embryos. *Curr. Top. Dev. Biol.* **39**: 73–117.
- Brenner, S. 1974. The genetics of *Caenorhabditis elegans*. *Genetics* **77**: 71–94.
- Burns, C.G., Ohi, R., Mehta, S., O'Toole, E.T., Winey, M., Clark, T.A., Sugnet, C.W., Ares Jr., M., and Gould, K.L. 2002. Removal of a single α -tubulin gene intron suppresses cell cycle arrest phenotypes of splicing factor mutations in *Saccharomyces cerevisiae*. *Mol. Cell. Biol.* **22**: 801–815.
- Busino, L., Donzelli, M., Chiesa, M., Guardavaccaro, D., Ganoth, D., Dorrello, N.V., Hershko, A., Pagano, M., and Draetta, G.F. 2003. Degradation of Cdc25A by β -TrCP during S phase and in response to DNA damage. *Nature* **426**: 87–91.
- Busino, L., Chiesa, M., Draetta, G.F., and Donzelli, M. 2004. Cdc25A phosphatase: Combinatorial phosphorylation, ubiquitylation, and proteolysis. *Oncogene* **23**: 2050–2056.
- Chakarova, C.F., Hims, M.M., Bolz, H., Abu-Safieh, L., Patel, R.J., Papaioannou, M.G., Inglehearn, C.F., Keen, T.J., Willis, C., Moore, A.T., et al. 2002. Mutations in HPRP3, a third member of pre-mRNA splicing factor genes, implicated in autosomal dominant retinitis pigmentosa. *Hum. Mol. Genet.* **11**: 87–92.
- Clucas, C., Cabello, J., Bussing, I., Schnabel, R., and Johnstone, I.L. 2002. Oncogenic potential of a *C.elegans cdc25* gene is demonstrated by a gain-of-function allele. *EMBO J.* **21**: 665–674.
- Coelho, C.M., Kolevski, B., Walker, C.D., Lavagi, I., Shaw, T., Ebert, A., Leever, S.J., and Marygold, S.J. 2005. A genetic screen for dominant modifiers of a small-wing phenotype in *Drosophila melanogaster* identifies proteins involved in splicing and translation. *Genetics* **171**: 597–614.
- Courtot, C., Fankhauser, C., Simanis, V., and Lehner, C.F. 1992. The *Drosophila cdc25* homolog *twine* is required for meiosis. *Development* **116**: 405–416.
- Dahan, O. and Kupiec, M. 2002. Mutations in genes of *Saccharomyces cerevisiae* encoding pre-mRNA splicing factors cause cell cycle arrest through activation of the spindle checkpoint. *Nucleic Acids Res.* **30**: 4361–4370.
- Dahan, O. and Kupiec, M. 2004. The *Saccharomyces cerevisiae* gene CDC40/PRP17 controls cell cycle progression through splicing of the ANC1 gene. *Nucleic Acids Res.* **32**: 2529–2540.
- Deckert, J., Hartmuth, K., Boehringer, D., Behzadnia, N., Will, C.L., Kastner, B., Stark, H., Urlaub, H., and Luhrmann, R. 2006. Protein composition and electron microscopy structure of affinity-purified human spliceosomal B complexes isolated under physiological conditions. *Mol. Cell. Biol.* **26**: 5528–5543.
- DeRenzo, C. and Seydoux, G. 2004. A clean start: Degradation of maternal proteins at the oocyte-to-embryo transition. *Trends Cell Biol.* **14**: 420–426.
- Dibb, N.J., Brown, D.M., Karn, J., Moerman, D.G., Bolten, S.L., and Waterston, R.H. 1985. Sequence analysis of mutations that affect the synthesis, assembly and enzymatic activity of the unc-54 myosin heavy chain of *Caenorhabditis elegans*. *J. Mol. Biol.* **183**: 543–551.
- Edgar, B.A. 1994. Cell-cycle control in a developmental context. *Curr. Biol.* **4**: 522–524.

- Edgar, L.G. and McGhee, J.D. 1988. DNA synthesis and the control of embryonic gene expression in *C. elegans*. *Cell* **53**: 589–599.
- Edgar, B.A. and Datar, S.A. 1996. Zygotic degradation of two maternal Cdc25 mRNAs terminates *Drosophila*'s early cell cycle program. *Genes & Dev.* **10**: 1966–1977.
- Edgar, B.A. and Lehner, C.F. 1996. Developmental control of cell cycle regulators: A fly's perspective. *Science* **274**: 1646–1652.
- Evsikov, A.V., Graber, J.H., Brockman, J.M., Hampl, A., Holbrook, A.E., Singh, P., Eppig, J.J., Solter, D., and Knowles, B.B. 2006. Cracking the egg: Molecular dynamics and evolutionary aspects of the transition from the fully grown oocyte to embryo. *Genes & Dev.* **20**: 2713–2727.
- Falck, J., Mailand, N., Syljuasen, R.G., Bartek, J., and Lukas, J. 2001. The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. *Nature* **410**: 842–847.
- Faustino, N.A. and Cooper, T.A. 2003. Pre-mRNA splicing and human disease. *Genes & Dev.* **17**: 419–437.
- Fukushige, T., Hendzel, M.J., Bazett-Jones, D.P., and McGhee, J.D. 1999. Direct visualization of the elt-2 gut-specific GATA factor binding to a target promoter inside the living *Caenorhabditis elegans* embryo. *Proc. Natl. Acad. Sci.* **96**: 11883–11888.
- Galaktionov, K. and Beach, D. 1991. Specific activation of cdc25 tyrosine phosphatases by B-type cyclins: Evidence for multiple roles of mitotic cyclins. *Cell* **67**: 1181–1194.
- Gonczy, P., Echeverri, C., Oegema, K., Coulson, A., Jones, S.J., Copley, R.R., Duperon, J., Oegema, J., Brehm, M., Cassin, E., et al. 2000. Functional genomic analysis of cell division in *C. elegans* using RNAi of genes on chromosome III. *Nature* **408**: 331–336.
- Gonzalez-Santos, J.M., Cao, H., Duan, R.C., and Hu, J. 2008. Mutation in the splicing factor Hprp3p linked to retinitis pigmentosa impairs interactions within the U4/U6 snRNP complex. *Hum. Mol. Genet.* **17**: 225–239.
- Grainger, R.J. and Beggs, J.D. 2005. Prp8 protein: At the heart of the spliceosome. *RNA* **11**: 533–557.
- Habara, Y., Urushiyama, S., Shibuya, T., Ohshima, Y., and Tani, T. 2001. Mutation in the *prp12*⁺ gene encoding a homolog of SAPI30/SF3b130 causes differential inhibition of pre-mRNA splicing and arrest of cell-cycle progression in *Schizosaccharomyces pombe*. *RNA* **7**: 671–681.
- Hartwell, L.H. 1967. Macromolecule synthesis in temperature-sensitive mutants of yeast. *J. Bacteriol.* **93**: 1662–1670.
- Heasman, J. 2006. Patterning the early *Xenopus* embryo. *Development* **133**: 1205–1217.
- Hebeisen, M. and Roy, R. 2008. CDC-25.1 stability is regulated by distinct domains to restrict cell division during embryogenesis in *C. elegans*. *Development* **135**: 1259–1269.
- Hodges, P.E., Jackson, S.P., Brown, J.D., and Beggs, J.D. 1995. Extraordinary sequence conservation of the PRP8 splicing factor. *Yeast* **11**: 337–342.
- Hodgkin, J. and Doniach, T. 1997. Natural variation and copulatory plug formation in *Caenorhabditis elegans*. *Genetics* **146**: 149–164.
- Hodgkin, J., Papp, A., Pulak, R., Ambros, V., and Anderson, P. 1989. A new kind of informational suppression in the nematode *Caenorhabditis elegans*. *Genetics* **123**: 301–313.
- Jin, J., Shirogane, T., Xu, L., Nalepa, G., Qin, J., Elledge, S.J., and Harper, J.W. 2003. SCFbeta-TRCP links Chk1 signaling to degradation of the Cdc25A protein phosphatase. *Genes & Dev.* **17**: 3062–3074.
- Kamath, R.S., Fraser, A.G., Dong, Y., Poulin, G., Durbin, R., Gotta, M., Kanapin, A., Le Bot, N., Moreno, S., Sohrmann, M., et al. 2003. Systematic functional analysis of the *Caenorhabditis elegans* genome using RNAi. *Nature* **421**: 231–237.
- Kaplan, Y. and Kupiec, M. 2007. A role for the yeast cell cycle/splicing factor Cdc40 in the G1/S transition. *Curr. Genet.* **51**: 123–140.
- Kennan, A., Aherne, A., and Humphries, P. 2005. Light in retinitis pigmentosa. *Trends Genet.* **21**: 103–110.
- Kim, S.H., Li, C., and Maller, J.L. 1999. A maternal form of the phosphatase Cdc25A regulates early embryonic cell cycles in *Xenopus laevis*. *Dev. Biol.* **212**: 381–391.
- Kipreos, E.T. 2005. *C. elegans* cell cycles: Invariance and stem cell divisions. *Nat. Rev. Mol. Cell Biol.* **6**: 766–776.
- Kostic, I. and Roy, R. 2002. Organ-specific cell division abnormalities caused by mutation in a general cell cycle regulator in *C. elegans*. *Development* **129**: 2155–2165.
- Lecuyer, E., Yoshida, H., Parthasarathy, N., Alm, C., Babak, T., Cerovina, T., Hughes, T.R., Tomancak, P., and Krause, H.M. 2007. Global analysis of mRNA localization reveals a prominent role in organizing cellular architecture and function. *Cell* **131**: 174–187.
- Lin, R. 2003. A gain-of-function mutation in oma-1, a *C. elegans* gene required for oocyte maturation, results in delayed degradation of maternal proteins and embryonic lethality. *Dev. Biol.* **258**: 226–239.
- Longman, D., Plasterk, R.H., Johnstone, I.L., and Caceres, J.F. 2007. Mechanistic insights and identification of two novel factors in the *C. elegans* NMD pathway. *Genes & Dev.* **21**: 1075–1085.
- Lundgren, K., Allan, S., Urushiyama, S., Tani, T., Ohshima, Y., Frendewey, D., and Beach, D. 1996. A connection between pre-mRNA splicing and the cell cycle in fission yeast: *cdc28*⁺ is allelic with *prp8*⁺ and encodes an RNA-dependent ATPase/helicase. *Mol. Biol. Cell* **7**: 1083–1094.
- Maduro, M.F., Hill, R.J., Heid, P.J., Newman-Smith, E.D., Zhu, J., Priess, J.R., and Rothman, J.H. 2005. Genetic redundancy in endoderm specification within the genus *Caenorhabditis*. *Dev. Biol.* **284**: 509–522.
- Maïta, H., Kitaura, H., Keen, T.J., Inglehearn, C.F., Ariga, H., and Iguchi-Ariga, S.M. 2004. PAP-1, the mutated gene underlying the RP9 form of dominant retinitis pigmentosa, is a splicing factor. *Exp. Cell Res.* **300**: 283–296.
- Maïta, H., Kitaura, H., Ariga, H., and Iguchi-Ariga, S.M. 2005. Association of PAP-1 and Prp3p, the products of causative genes of dominant retinitis pigmentosa, in the tri-snRNP complex. *Exp. Cell Res.* **302**: 61–68.
- Makarov, E.M., Makarova, O.V., Urlaub, H., Gentzel, M., Will, C.L., Wilm, M., and Lührmann, R. 2002. Small nuclear ribonucleoprotein remodeling during catalytic activation of the spliceosome. *Science* **298**: 2205–2208.
- Makarova, O.V., Makarov, E.M., Liu, S., Vornlocher, H.P., and Lührmann, R. 2002. Protein 61K, encoded by a gene (PRPF31) linked to autosomal dominant retinitis pigmentosa, is required for U4/U6*U5 tri-snRNP formation and pre-mRNA splicing. *EMBO J.* **21**: 1148–1157.
- Marone, M., Mozzetti, S., De Ritis, D., Pierelli, L., and Scambia, G. 2001. Semiquantitative RT-PCR analysis to assess the expression levels of multiple transcripts from the same sample. *Biol. Proced. Online* **3**: 19–25.
- Mata, J., Curado, S., Ephrussi, A., and Rorth, P. 2000. Tribbles coordinates mitosis and morphogenesis in *Drosophila* by regulating string/CDC25 proteolysis. *Cell* **101**: 511–522.
- McKie, A.B., McHale, J.C., Keen, T.J., Tarttlin, E.E., Goliath, R., van Lith-Verhoeven, J.J., Greenberg, J., Ramesar, R.S., Hoyng, C.B., Cremers, F.P., et al. 2001. Mutations in the pre-mRNA splicing factor gene PRPC8 in autosomal dominant retinitis pigmentosa (RP13). *Hum. Mol. Genet.* **10**: 1555–1562.
- Mordes, D., Luo, X., Kar, A., Kuo, D., Xu, L., Fushimi, K., Yu, G., Sternberg Jr., P., and Wu, J.Y. 2006. Pre-mRNA splicing and retinitis pigmentosa. *Mol. Vis.* **12**: 1259–1271.
- Mueller, P.R., Coleman, T.R., Kumagai, A., and Dunphy, W.G. 1995. Myt1: A membrane-associated inhibitory kinase that phosphorylates Cdc2 on both threonine-14 and tyrosine-15. *Science* **270**: 86–90.
- Myer, D.L., Bahassi, E.M., and Stambrook, P.J. 2005. The Plk3-Cdc25 circuit. *Oncogene* **24**: 299–305.
- Newport, J. and Kirschner, M. 1982. A major developmental transition in early *Xenopus* embryos: I. characterization and timing of cellular changes at the midblastula stage. *Cell* **30**: 675–686.

- Nishi, Y. and Lin, R. 2005. DYRK2 and GSK-3 phosphorylate and promote the timely degradation of OMA-1, a key regulator of the oocyte-to-embryo transition in *C. elegans*. *Dev. Biol.* **288**: 139–149.
- O'Farrell, P.H., Edgar, B.A., Lakich, D., and Lehner, C.F. 1989. Directing cell division during development. *Science* **246**: 635–640.
- Pena, V., Liu, S., Bujnicki, J.M., Luhrmann, R., and Wahl, M.C. 2007. Structure of a multipartite protein–protein interaction domain in splicing factor prp8 and its link to retinitis pigmentosa. *Mol. Cell* **25**: 615–624.
- Perdiguerro, E. and Nebreda, A.R. 2004. Regulation of Cdc25C activity during the meiotic G2/M transition. *Cell Cycle* **3**: 733–737.
- Potashkin, J., Kim, D., Fons, M., Humphrey, T., and Frendewey, D. 1998. Cell-division-cycle defects associated with fission yeast pre-mRNA splicing mutants. *Curr. Genet.* **34**: 153–163.
- Praitis, V., Casey, E., Collar, D., and Austin, J. 2001. Creation of low-copy integrated transgenic lines in *Caenorhabditis elegans*. *Genetics* **157**: 1217–1226.
- Rasheva, V.I., Knight, D., Bozko, P., Marsh, K., and Frolov, M.V. 2006. Specific role of the SR protein splicing factor B52 in cell cycle control in *Drosophila*. *Mol. Cell. Biol.* **26**: 3468–3477.
- Reese, K.J., Dunn, M.A., Waddle, J.A., and Seydoux, G. 2000. Asymmetric segregation of PIE-1 in *C. elegans* is mediated by two complementary mechanisms that act through separate PIE-1 protein domains. *Mol. Cell* **6**: 445–455.
- Rio Frio, T., Wade, N.M., Ransijn, A., Berson, E.L., Beckmann, J.S., and Rivolta, C. 2008. Premature termination codons in PRPF31 cause retinitis pigmentosa via haploinsufficiency due to nonsense-mediated mRNA decay. *J. Clin. Invest.* **118**: 1519–1531.
- Rushforth, A.M. and Anderson, P. 1996. Splicing removes the *Caenorhabditis elegans* transposon Tc1 from most mutant pre-mRNAs. *Mol. Cell. Biol.* **16**: 422–429.
- Russell, P. and Nurse, P. 1987. Negative regulation of mitosis by *wee1+*, a gene encoding a protein kinase homolog. *Cell* **49**: 559–567.
- Russell, C.S., Ben-Yehuda, S., Dix, I., Kupiec, M., and Beggs, J.D. 2000. Functional analyses of interacting factors involved in both pre-mRNA splicing and cell cycle progression in *Saccharomyces cerevisiae*. *RNA* **6**: 1565–1572.
- Shea, J.E., Toyn, J.H., and Johnston, L.H. 1994. The budding yeast U5 snRNP Prp8 is a highly conserved protein which links RNA splicing with cell cycle progression. *Nucleic Acids Res.* **22**: 5555–5564.
- Shimuta, K., Nakajo, N., Uto, K., Hayano, Y., Okazaki, K., and Sagata, N. 2002. Chk1 is activated transiently and targets Cdc25A for degradation at the *Xenopus* midblastula transition. *EMBO J.* **21**: 3694–3703.
- Shirayama, M., Soto, M.C., Ishidate, T., Kim, S., Nakamura, K., Bei, Y., van den Heuvel, S., and Mello, C.C. 2006. The conserved kinases CDK-1, GSK-3, KIN-19, and MBK-2 promote OMA-1 destruction to regulate the oocyte-to-embryo transition in *C. elegans*. *Curr. Biol.* **16**: 47–55.
- Sorensen, C.S., Syljuasen, R.G., Falck, J., Schroeder, T., Ronnstrand, L., Khanna, K.K., Zhou, B.B., Bartek, J., and Lukas, J. 2003. Chk1 regulates the S phase checkpoint by coupling the physiological turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A. *Cancer Cell* **3**: 247–258.
- Stitzel, M.L., Pellettieri, J., and Seydoux, G. 2006. The *C. elegans* DYRK kinase MBK-2 marks oocyte proteins for degradation in response to meiotic maturation. *Curr. Biol.* **16**: 56–62.
- Teigelkamp, S., Newman, A.J., and Beggs, J.D. 1995. Extensive interactions of PRP8 protein with the 5' and 3' splice sites during splicing suggest a role in stabilization of exon alignment by U5 snRNA. *EMBO J.* **14**: 2602–2612.
- Vijayraghavan, U., Company, M., and Abelson, J. 1989. Isolation and characterization of pre-mRNA splicing mutants of *Saccharomyces cerevisiae*. *Genes & Dev.* **3**: 1206–1216.
- Vithana, E.N., Abu-Safieh, L., Allen, M.J., Carey, A., Papaioannou, M., Chakarova, C., Al-Magthteh, M., Ebenezer, N.D., Willis, C., Moore, A.T., et al. 2001. A human homolog of yeast pre-mRNA splicing gene, PRP31, underlies autosomal dominant retinitis pigmentosa on chromosome 19q13.4 (RP11). *Mol. Cell* **8**: 375–381.
- Wang, Q.T., Piotrowska, K., Ciemerych, M.A., Milenkovic, L., Scott, M.P., Davis, R.W., and Zernicka-Goetz, M. 2004. A genome-wide study of gene activity reveals developmental signaling pathways in the preimplantation mouse embryo. *Dev. Cell* **6**: 133–144.
- Wicks, S.R., Yeh, R.T., Gish, W.R., Waterston, R.H., and Plasterk, R.H. 2001. Rapid gene mapping in *Caenorhabditis elegans* using a high density polymorphism map. *Nat. Genet.* **28**: 160–164.
- Zhang, L., Shen, J., Guarnieri, M.T., Heroux, A., Yang, K., and Zhao, R. 2007. Crystal structure of the C-terminal domain of splicing factor Prp8 carrying retinitis pigmentosa mutants. *Protein Sci.* **16**: 1024–1031.

RNA

A PUBLICATION OF THE RNA SOCIETY

Suppressors of the *cdc-25.1(gf)*-associated intestinal hyperplasia reveal important maternal roles for *prp-8* and a subset of splicing factors in *C. elegans*

Michaël Hebeisen, John Drysdale and Richard Roy

RNA 2008 14: 2618-2633 originally published online October 22, 2008

Access the most recent version at doi:[10.1261/rna.1168408](https://doi.org/10.1261/rna.1168408)

Supplemental Material

<http://rnajournal.cshlp.org/content/suppl/2008/10/23/rna.1168408.DC1>

References

This article cites 90 articles, 36 of which can be accessed free at:
<http://rnajournal.cshlp.org/content/14/12/2618.full.html#ref-list-1>

License

Email Alerting Service

Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or [click here](#).

To subscribe to *RNA* go to:

<http://rnajournal.cshlp.org/subscriptions>